Long Term Safety of 125 mg Per Day of Oral Azimilide in Patients With Implantable Cardioverter Defibrillator (ICDs)

Completed · Phase 3

Conditions studied: Arrhythmias

In brief

This is an open-label, multi-center, long-term, (open-ended) safety study with 125 mg per day of azimilide in patients who completed protocol 2000098.

Key facts

Study ID

NCT00751738

Run by

Forest Laboratories

People needed

330

Starts

2002-10-01

Expected to finish

2005-10-01

Last updated by the study team

2017-02-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• patients who completed at least 12 months on study 2000098 before inclusion in this study

You may not qualify if…

• breast feeding or plan to become pregnant
• used ticlopidine
• were taking Class I or other Class III drugs

Where it is running

• Research Facility — Little Rock, Arkansas, United States
• Research Facility — La Jolla, California, United States
• Research Facility — Loma Linda, California, United States
• Research Facility — Sacramento, California, United States
• Research Facility — Colorado Springs, Colorado, United States
• Research Facility — Bridgeport, Connecticut, United States
• Research Facility — Washington D.C., District of Columbia, United States
• Research Facility — Fort Lauderdale, Florida, United States
• Research Facility — Fort Myers, Florida, United States
• Research Facility — Jacksonville, Florida, United States
• Research Facility — Maywood, Illinois, United States
• Research Facility — Kansas City, Kansas, United States
• Research Facility — Portland, Maine, United States
• Research Facility — Baltimore, Maryland, United States
• Research Facility — Baltimore, Maryland, United States
• Research Facility — Boston, Massachusetts, United States
• Research Facility — Burlington, Massachusetts, United States
• Research Facility — Worcester, Massachusetts, United States
• Research Facility — Warren Township, New Jersey, United States
• Research Facility — Brooklyn, New York, United States
• Research Facility — Johnson City, New York, United States
• Research Facility — New York, New York, United States
• Research Facility — New York, New York, United States
• Research Facility — Rochester, New York, United States
• Research Facility — Mobile, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.